Immune cell promotion of metastasis

Author(s): Kitamura T, Qian BZ, Pollard JW

Abstract

Metastatic disease is the major cause of death from cancer, and immunotherapy and chemotherapy have had limited success in reversing its progression. Data from mouse models suggest that the recruitment of immunosuppressive cells to tumours protects metastatic cancer cells from surveillance by killer cells, which nullifies the effects of immunotherapy and thus establishes metastasis. Furthermore, in most cases, tumour-infiltrating immune cells differentiate into cells that promote each step of the metastatic cascade and thus are novel targets for therapy. In this Review, we describe how tumour-infiltrating immune cells contribute to the metastatic cascade and we discuss potential therapeutic strategies to target these cells.

Similar Articles

Role of altered expression of HLA class I molecules in cancer progression

Author(s): Aptsiauri N, Cabrera T, Mendez R, Garcia-Lor A, Ruiz-Cabello F, et al.

β-Arrestin-dependent, G protein-independent ERK1/2 activation by the 2-adrenergic receptor

Author(s): Shenoy SK, Drake MT, Nelson CD, Houtz DA, Xiao K, et al.

Human T cell responses against melanoma

Author(s): Boon T, Coulie PG, Van Den Eynde BJ, Van Der Bruggen P

Mutations in GNA11 in Uveal Melanoma

Author(s): Van Raamsdonk C, Griewank K, Michelle B, Crosby MB, Garrido MC, et al.

Cohesin‐SA1 deficiency drives aneuploidy and tumourigenesis in mice due to impaired replication of telomeres

Author(s): Remeseiro S, Cuadrado A, Carretero M, Martínez P, Drosopoulos WC, et al.

MDM4 is a key therapeutic target in cutaneous melanoma

Author(s): Gembarska A, Luciani F, Fedele C, Russell EA, Dewaele A, et al.

Epithelial–mesenchymal transition in cancer development and its clinical significance

Author(s): Iwatsuki M, Mimori K, Yokobori T, Ishi H, Beppu T, et al.

RAGE is the major receptor for the proinflammatory activity of HMGB1 in rodent macrophages

Author(s): Kokkola R, Andersson A, Mullins G, Östberg T, Treutiger CJ, et al.

CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms

Author(s): Parry RV, Chemnitz JM, Frauwirth KA, Lanfranco AR, Braunstein I, et al.

The epithelial-mesenchymal transition generates cells with properties of stem cells

Author(s): Mani A, Guo W, Liao MJ, Eaton E, Ayyanan A, et al.

B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells

Author(s): Azuma T, Yao S, Zhu G, Flies A, Flies S, et al.

Breast cancer version 3

Author(s): Gradishar W, Anderson B, Blair S, Burstein H, Cyr A, et al.

In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas

Author(s): Schalper K, Velcheti V, Carvajal D, Wimberly H, Brown J, et al.

Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer

Author(s): Muenst S, Schaerli AR, Gao F, Däster S, Trella E, et al.

Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer

Author(s): Twyman-Saint VC, Rech AJ, Maity A, Rengan R, Pauken KE, et al.

Aspirin and P2Y12 inhibition attenuate platelet-induced ovarian cancer cell invasion

Author(s): Cooke NM, Spillane CD, Sheils O, O’Leary J, Kenny D

FOXP3+regulatory T cells affect the development and progression of hepatocarcinogenesis

Author(s): Kobayashi N, Hiraoka N, Yamagami W, Ojima H, Kanai Y, et al.

Methylation not a frequent “second hit” in tumors with germline BRCA mutations

Author(s): Dworkin AM, Spearman A, Tseng S, Sweet K, Amanda AE

Epithelial-mesenchymal transitions in development and disease

Author(s): Thiery JP, Acloque H, Huang R, Nieto A

Molecular biomarker in prostate cancer: The role of CpG island hypermethylation

Author(s): Bastian P, Yegnasubramanian S, Palapattu G, Rogers C, Lin X, et al.

Molecular epigenetics and genetics in neuro-oncology

Author(s): Nagarajan R, Costello J